• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Erasmus MC Biomedical Fund

edit

The Erasmus MC Biomedical Fund is an independent venture capital fund focusing on early stage companies and (university) spin-outs in the biotechnology and biomedical field with a presence in the Rotterdam region.

The fund targets companies that are developing commercially promising products and technologies in life sciences, including: pharmaceuticals, biotechnology, information technology and other high technology opportunities that offer venture capital returns.

Recent Milestones

edit

• 
  Erasmus MC Biomedical Fund invested in arGEN-X. (12/1/11)
  Posted 12/1/11 at 5:11am via finsmes.com
• 
  Erasmus MC Biomedical Fund invested in arGEN-X. (2/11/10)
  Posted 2/15/10 at 6:25pm via onbiovc.com
• 
  Erasmus MC Biomedical Fund invested in arGEN-X. (9/10/09)
  Posted 9/14/09 at 6:17am via fiercebiotech.com
• 
  Erasmus MC Biomedical Fund invested in Therosteon. (4/1/08)
  Posted 5/26/09 at 1:40am

Investments

Videos

Sources

1. arGEN-X Closes €27.5M Series B Funding Round (finsmes.com) [edit]
2. arGEN-X, BV: Series A $4.5M (onbiovc.com) [edit]
3. arGEN-X gins $13.6M in new funds for mAB work (fiercebiotech.com) [edit]
4. Capital Funding Report [edit]